Form 4 for AVTX Avalo Therapeutics, Inc.

Accepted 2023-05-22 00:00:00 ET · period of report 2023-05-18 · accession 0001929354-23-000009 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2023-05-22	2023-05-18+	AVTX	Caissa Capital Management ltd.	10%	P - Purchase	$3.36	+26.6K	1.37M	+2%	+$89.4K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common stock	2023-05-19	P	A	6,500	$3.52	1,366,700	I See Footnote (1)	—	—	(F3) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4 to $3.6, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
2	Common	Common stock	2023-05-18	P	A	13,121	$3.29	1,360,200	I See Footnote (1)	—	—	(F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.80 to $3.40, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
3	Common	Common stock	2023-05-22	P	A	7,000	$3.34	1,373,700	I See Footnote (1)	—	—	(F4) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.72, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.